Table 3.

Association between serum IL-6 concentrations and flavonol intake during the trial, stratified by baseline IL-6 concentrations (n = 872)

IL-6 (T0) tertiles* (pg/mL)Flavonol intake quartiles (mg/d)*P
Q1: <21.2Q2: 21.2-29.7Q3: 29.8-40.0Q4: >40.0
Median (IQR)Median (IQR)Median (IQR)Median (IQR)
IL-6 (T0) <1.53*
    Sample size65717976
    Trial (T1,3)1.47 (1.15-1.84)1.49 (1.19-1.90)1.35 (1.01-1.72)1.44 (1.07-1.75)0.22
    Change (T1,3-T0)0.34 (0.00-0.58)0.36 (0.02-0.69)0.20 (−0.05-0.49)0.30 (0.01-0.58)0.15
IL-6 (T0) 1.53-2.37*
    Sample size72737373
    Trial (T1,3)2.07 (1.68-2.52)2.12 (1.79-2.69)1.93 (1.62-2.49)1.90 (1.52-2.50)0.29
    Change (T1,3-T0)0.22 (−0.17-0.51)0.33 (−0.22-0.76)0.12 (−0.31-0.49)−0.08 (−0.37-0.42)0.13
IL-6 (T0) >2.37*
    Sample size81746669
    Trial (T1,3)3.39 (2.45-4.66)3.14 (2.15-4.90)2.72 (2.09-4.11)2.63 (1.77-3.56)0.01
    Change (T1,3-T0)−0.26 (−1.15-0.66)−0.90 (−2.31-0.26)−0.76 (−1.91-0.15)−0.75 (−1.65-0.01)0.05
  • *Participants were grouped in tertiles by their baseline IL-6 concentrations (T0) and in quartiles (Q1-Q4) by mean flavonol intake during the first 3 trial years.

  • P values for differences in medians among the flavonol intake quartiles within baseline IL-6 tertiles were calculated based on the Kruskal-Wallis test. The P value for trend using a multiple regression model adjusting for age tertiles (<58, 58-66, >66 y), sex, average BMI (<25, 25.0-29.9, ≥30 kg/m2), current smoking status, and average energy intake (continuous) during the first 3 trial years was 0.008 for Trial (T1,3) and 0.02 for Change (T1,3-T0) for the highest baseline IL-6 tertile.

  • Trial (T1,3) = geometric mean of year 1 and year 3 values. Change (T1,3-T0) = T1,3 minus baseline values.